Entrada Therapeutics reports clinical-stage biopharmaceutical developments tied to its intracellular genetic-medicine platform and Endosomal Escape Vehicle therapeutics. Company updates center on RNA-based and oligonucleotide programs for neuromuscular and inherited retinal diseases, including Duchenne muscular dystrophy programs for exon 44, 45, 50 and 51 skipping-amenable patients.
Recurring news includes clinical data and study progress for ELEVATE programs, updates on ENTR-601-44 and other DMD candidates, the partnered VX-670 program for myotonic dystrophy type 1, and pipeline expansion into ocular disease such as Usher syndrome. Financial results, cash runway commentary, investor conference participation and Nasdaq inducement equity grants also appear in company communications.
Azenta (NASDAQ: AZTA) announced the election of Dipal Doshi to its Board of Directors at its Annual Meeting of Stockholders. Doshi, who currently serves as the Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA), brings extensive experience in the biotechnology and pharmaceutical industries.
John Marotta, President and CEO of Azenta, highlighted Doshi's exceptional leadership qualities and valuable experience in strategy, operational and commercial growth, along with his perspective as a current public company CEO. Doshi expressed enthusiasm about joining Azenta during a important period in its development, emphasizing the company's strong market leadership position and commitment to growth and innovation.
Entrada Therapeutics (Nasdaq: TRDA), a clinical-stage biopharmaceutical company focused on developing medicines for intracellular targets, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Dipal Doshi will deliver a presentation on Wednesday, January 15, 2025, at 11:15 a.m. PT (2:15 p.m. ET).
The presentation will be accessible via live webcast on the company's Investor Relations website, with a replay available for 30 days following the event. Entrada's mission centers on transforming patient lives by creating innovative treatments that can reach previously inaccessible intracellular targets.
Entrada Therapeutics (NASDAQ: TRDA) reported Q3 2024 financial results with a net loss of $14.0 million, compared to net income of $35.5 million in Q3 2023. The company reported $449.3 million in cash, cash equivalents and marketable securities, extending runway into 2027. Collaboration revenue decreased to $19.6 million from $43.7 million year-over-year. R&D expenses increased to $31.3 million from $22.2 million, while G&A expenses rose to $10.0 million from $7.5 million.
The company presented additional Phase 1 clinical trial data for ENTR-601-44 and new preclinical data for ENTR-601-45 at the World Muscle Society Congress. Global regulatory filings for Phase 2 trials of both compounds are planned for Q4 2024.
Entrada Therapeutics (Nasdaq: TRDA) presented new data supporting its Duchenne franchise at the 29th Annual Congress of the World Muscle Society. The company shared additional positive data from its completed Phase 1 trial of ENTR-601-44, reinforcing its safety profile and supporting planned Q4 2024 global regulatory filings for a Phase 2 trial. Preclinical data for ENTR-601-45 showed exon skipping and dystrophin production, supporting planned Q4 2024 regulatory filings for a global direct-to-patient Phase 2 trial.
Key highlights include:
- No adverse findings or clinically relevant changes to renal toxicity biomarkers at the highest dose tested for ENTR-601-44
- Statistically significant differences in exon skipping between 6 mg/kg and placebo administrations
- ENTR-601-45 produced robust dose-dependent exon skipping and dystrophin restoration in preclinical models
- Improved skeletal muscle function in an exon 45 skip-amenable DMD mouse model
Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company, has promoted Natarajan Sethuraman, PhD, to President of Research and Development. Dr. Sethuraman, previously the Chief Scientific Officer, has been with Entrada since its inception and has played a important role in advancing the company's ENTR-601-44 program into clinical trials. His leadership has been instrumental in building Entrada's pipeline of proprietary intracellular therapeutics.
CEO Dipal Doshi praised Dr. Sethuraman's contributions, highlighting his experience in end-to-end therapeutics development. Dr. Sethuraman expressed excitement about Entrada's approach to intracellular therapeutics and the potential to reach previously inaccessible targets. He joined Entrada in 2017 and has since led global research and clinical development, building an R&D team advancing a portfolio of programs from discovery through clinical development.
āshibio, a clinical-stage biotech company, has appointed Dipal Doshi to its Board of Directors. Doshi, currently CEO of Entrada Therapeutics (NASDAQ: TRDA), brings extensive experience in biopharmaceutical strategy and growth. āshibio, which emerged from stealth mode in June 2024 with $40 million in seed and Series A funding, is developing therapies for bone and connective tissue disorders, including a potential treatment for fibrodysplasia ossificans progressiva (FOP).
Doshi's appointment is expected to contribute significantly to āshibio's next growth phase, leveraging his operational and fundraising expertise. His track record includes advancing Entrada's pipeline, completing private financings, leading its IPO, and executing a major business development collaboration.
Entrada Therapeutics (NASDAQ: TRDA) reported positive Q2 2024 financial results and clinical progress. Key highlights include:
1. Positive Phase 1 data for ENTR-601-44 in DMD, showing dose-dependent plasma and muscle concentration, and exon skipping.
2. Planning for global Phase 2 trials for ENTR-601-44 and ENTR-601-45, with regulatory filings expected in Q4 2024.
3. Completed a $100 million registered direct offering, extending cash runway into 2027.
4. Strong financial position with $470 million in cash and equivalents as of June 30, 2024.
5. Q2 collaboration revenue of $94.7 million, up from $18.2 million in Q2 2023.
6. Net income of $55.0 million for Q2 2024, compared to a net loss of $25.9 million in Q2 2023.
Entrada Therapeutics (Nasdaq: TRDA), a clinical-stage biopharmaceutical company, announced a $100 million registered direct offering. The purchase involves 3,367,003 shares of common stock and pre-funded warrants to purchase an equal amount of common stock. The offering price per share is $14.85, while the pre-funded warrants are priced slightly lower at $14.8499 due to a minimal exercise price of $0.0001 per warrant. The offering is led by a U.S. healthcare investor, two global mutual funds, and Janus Henderson Investors. The funds will support ongoing clinical trials, research, and other corporate needs. The transaction is expected to close around June 25, 2024, subject to customary conditions.
Entrada Therapeutics (Nasdaq: TRDA) has reported positive preliminary data from its Phase 1 trial ENTR-601-44-101 for Duchenne Muscular Dystrophy (DMD). The drug, ENTR-601-44, was well tolerated, showing no serious adverse events. Significant plasma and muscle concentrations were observed, suggesting a clinically meaningful starting dose for Phase 2 trials. The trial included 32 healthy male volunteers, with doses ranging from 0.75 mg/kg to 6 mg/kg. The study demonstrated statistically significant exon skipping in the highest dose cohort, with plans for regulatory filings for Phase 2 trials in Q4 2024.
Entrada Therapeutics, a clinical-stage biopharmaceutical company listed on Nasdaq as TRDA, announces its participation in the Goldman Sachs 45th Annual Global Healthcare Conference. CEO Dipal Doshi will present in a fireside chat scheduled for June 10, 2024, at 4:00 p.m. ET in Miami, FL. The session will be webcast live on the company's website, with a replay available for 90 days.